Rewriting Immune Medicine with a Truly Revolutionary Platform
OmniAntigen™ delivers system-level immune reprogramming — hours, not weeks — for oncology and future immune-mediated diseases.
Novastra Therapeutics is a Boston-founded, clinical-stage biotech advancing Next-Generation Immune Reprogramming Therapy (NIRT) with the OmniAntigen™ platform. In under three hours, we convert patient- or pathogen-derived cells into room-temperature, gene-editing–free immune-reprogramming doses, enabling same-day, near-patient treatment. By preserving a full antigen spectrum and driving DC-first, STING-sensitized activation, OmniAntigen™ creates a combination-ready immune base layer for oncology today— and for future immune-mediated and infectious diseases.
About Novastra Therapeutics
Immuno-oncology is shifting from single-target modulation to system-level immune reprogramming — and Novastra is built for that future. We engineer immune-reprogramming doses that preserve a full antigen spectrum and provide built-in innate ignition—DC-first, STING-sensitized. OAP-1, our lead program, is in a first-in-human study in advanced solid tumors, demonstrating same-day, near-patient manufacturability and a pragmatic path to combinations. Next, we are extending OmniAntigen™ beyond oncology to pathogen-derived and cell-based programs for infectious and immune-mediated diseases, leveraging the same hours-not-weeks, closed-system workflow—no gene editing, no cryopreservation.
Our Mission
To make rapid, combination-ready immune reprogramming a global reality—delivering hours-not-weeks solutions that improve outcomes and lighten the treatment burden.
Our Approach
Immune Reprogramming Therapy
Each dose nanocloaks intact, patient- or pathogen-derived cells, preserving full antigen breadth and providing built-in innate activation for system-level immune reprogramming.
Clinical Program
OAP-1 is in a first-in-human study at a world-class academic center. Early work emphasizes safety/feasibility and translational endpoints (DC activity, type-I IFN/STING signatures, TCR diversity) to guide combination design.
Platform & Versatility
The same closed-system “nanocloak” workflow enables hours-level manufacturing and decentralized scale-out across solid tumors, pathogens, and immune-mediated disorders.
Global Integration
Boston-anchored science with decentralized, GMP-ready hubs supports regional deployment, efficient clinical learning, and partner-enabled manufacturing networks.
Patient Focus
< 3-hour turnaround reduces hospital visits and delays, enabling near-patient dosing and genuinely patient-centered care.
Execution Speed
Fully closed-system, GMP-compliant manufacturing—from production to dose in under three hours—empowers same-day treatment and scalable operations.
Advantages
Full-spectrum antigens to outpace heterogeneity and escape
DC-first, STING-sensitized innate-to-adaptive bridging
Hours-not-weeks closed-system manufacturing (near-patient)
Combination-ready immune base layer for PD-(L)1, TIL/TCR, oncolytics, and RT
Decentralized scale-out with clinic-friendly QC/QA
Multi-disease potential (oncology today; infectious/immune-mediated next)
Patient Stories*
*Individual results vary; OAP-1 currently investigational.
“Novastra Therapeutics has given me hope and a chance to fight cancer on my terms. Their personalized vaccine approach has made a significant impact on my treatment journey.”
“I am grateful to Novastra Therapeutics for their dedication to developing innovative cancer therapies. Their commitment to personalized care has truly made a difference in my life.”
“The team at Novastra Therapeutics goes above and beyond to ensure that patients like me receive the best possible care. Their compassionate approach has been a source of strength throughout my cancer treatment.”
Contact Us
